A Phase 1B Multiple Dose Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis.

Trial Profile

A Phase 1B Multiple Dose Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis.

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs SER 287 (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Seres Therapeutics
  • Most Recent Events

    • 04 Dec 2017 According to a Seres Therapeutics media release, the US FDA has granted Orphan Drug Designation to SER-287 based on the results of this trial. Phase 1b microbiome data from this trial are expected in early 2018.
    • 08 Nov 2017 Results published in a Seres Therapeutics Third Quarter 2017 Financial Results.
    • 02 Oct 2017 Status changed from active, no longer recruiting to completed according to a Seres Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top